Download File - JOHN J. HADDAD, Ph.D.

More documents

Recommendations

Info

Therapeutic and Prophylactic Cancer Vaccines 67 49. Sasagawa T, Pushko P, Steers G, et al. Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe. Virology 1995; 206(1):126–135. 50. Kirnbauer R, Booy F, Cheng N, et al. Papillomavirus L1 major capsid protein selfassembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992; 89(24):12180–12184. 51. Zhou J, Sun XY, Davies H, et al. Definition of linear antigenic regions of the HPV16 L1 capsid protein using synthetic virion-like particles. Virology 1992; 189(2):592–599. 52. Hagensee ME, Yaegashi N, Galloway DA. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol 1993; 67(1):315–322. 53. Breitburd F, Kirnbauer R, Hubbert NL, et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995; 69(6):3959–3963. 54. Suzich JA, Ghim SJ, Palmer-Hill FJ, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995; 92(25):11553–11557. 55. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6(5):271–278. 56. Villa LL, Ault KA, Giuliano AR, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 2006; 24(27–28):5571–5583. 57. De Bruijn ML, Greenstone HL, Vermeulen H, et al. L1-specific protection from tumor challenge elicited by HPV16 virus-like particles. Virology 1998; 250(2):371–376. 58. Selvakumar R, Borenstein LA, Lin YL, et al. Immunization with nonstructural proteins E1 and E2 of cottontail rabbit papillomavirus stimulates regression of virusinduced papillomas. J Virol 1995; 69(1):602–605. 59. Halpert R, Fruchter RG, Sedlis A, et al. Human papillomavirus and lower genital neoplasia in renal transplant patients. Obstet Gynecol 1986; 68(2):251–258. 60. Laga M, Icenogle JP, Marsella R, et al. Genital papillomavirus infection and cervical dysplasia: opportunistic complications of HIV infection. Int J Cancer 1992; 50(1):45–48. 61. Meyer T, Arndt R, Nindl I, et al. Association of human papillomavirus infections with cutaneous tumors in immunosuppressed patients. Transpl Int 2003; 16(3):146–153. 62. Petry KU, Scheffel D, Bode U, et al. Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions. Int J Cancer 1994; 57(6):836–840. 63. Benton C, Shahidullah H, Hunter JAA. Human papillomavirus in the immunosuppressed. Papillomavirus Report 1992:23–26. 64. Aiba S, Rokugo M, Tagami H. Immunohistologic analysis of the phenomenon of spontaneous regression of numerous flat warts. Cancer 1986; 58(6):1246–1251. 65. Iwatsuki K, Tagami H, Takigawa M, et al. Plane warts under spontaneous regression. Immunopathologic study on cellular constituents leading to the inflammatory reaction. Arch Dermatol 1986; 122(6):655–659. 66. Munger K, <strong>Ph</strong>elps WC, Bubb V, et al. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 1989; 63(10):4417–4421.
68 Srinivasan 67. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990; 248(4951):76–79. 68. Kim TY, Myoung HJ, Kim JH, et al. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4þ and CD8þ T cells in protection. Cancer Res 2002; 62(24):7234–7240. 69. de Gruijl TD, Bontkes HJ, Stukart MJ, et al. T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection. J Gen Virol 1996; 77(Pt. 9):2183–2191. 70. Tsukui T, Hildesheim A, Schiffman MH, et al. Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology. Cancer Res 1996; 56(17):3967–3974. 71. Nakagawa M, Stites DP, Farhat S, et al. Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia. J Infect Dis 1997; 175(4):927–931. 72. Nakagawa M, Stites DP, Patel S, et al. Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens. J Infect Dis 2000; 182(2):595–598. 73. Sin JI, Hong SH, Park YJ, et al. Antitumor therapeutic effects of e7 subunit and DNA vaccines in an animal cervical cancer model: antitumor efficacy of e7 therapeutic vaccines is dependent on tumor sizes, vaccine doses, and vaccine delivery routes. DNA Cell Biol 2006; 25(5):277–286. 74. Animal Medical Center. Canine Melanoma Vaccine Clinical Trial for USDA Licensure and Commercial Use. Animal Medical Center; 2007. 75. Fu DX, Tanhehco YC, Chen J, et al. Virus-associated tumor imaging by induction of viral gene expression. Clin Cancer Res 2007; 13(5):1453–1458.
Page 1 and 2:
Translational Medicine Series 6 Can
Page 3 and 4:
TRANSLATIONAL MEDICINE SERIES 1. Pr
Page 5 and 6:
Informa Healthcare USA, Inc. 52 Van
Page 8 and 9:
Preface Throughout the last 20 year
Page 10 and 11:
Preface vii Table 1 A Diverse Techn
Page 12 and 13:
Preface . . . . v Contributors . .
Page 14 and 15:
Contributors Pedro Alves Ludwig Ins
Page 16 and 17:
1 Factoring in Antigen Processing i
Page 18 and 19:
Factoring in Antigen Processing in
Page 20 and 21:
Page 22 and 23:
Page 24 and 25:
Page 26 and 27:
Page 28 and 29:
Page 30 and 31:
Page 32 and 33: Factoring in Antigen Processing in
Page 46 and 47: 2 Outlining the Gap Between Preclin
Page 48 and 49: Preclinical Models and Clinical Sit
Page 50 and 51: Table 1 Examples of Preclinical Act
Page 68: Preclinical Models and Clinical Sit
Page 71 and 72: 56 Srinivasan disease agents. Garda
Page 73 and 74: 58 Srinivasan expressing various kn
Page 75 and 76: 60 Srinivasan The above-mentioned a
Page 77 and 78: 62 Srinivasan (69). In another stud
Page 79 and 80: 64 Srinivasan patients with prostat
Page 81: 66 Srinivasan 33. Salgia R, Lynch T
Page 85 and 86: 70 Teofilovici and Wentworth In 190
Page 87 and 88: 72 Teofilovici and Wentworth conduc
Page 89 and 90: 74 Teofilovici and Wentworth Lipono
Page 91 and 92: 76 Teofilovici and Wentworth (best
Page 93 and 94: 78 Teofilovici and Wentworth nature
Page 95 and 96: 80 Teofilovici and Wentworth In the
Page 97 and 98: 82 Teofilovici and Wentworth 17. Ba
Page 99 and 100: 84 Luptrawan et al. Dendritic cells
Page 101 and 102: 86 Luptrawan et al. of cancer cells
Page 103 and 104: 88 Luptrawan et al. NK cells can ki
Page 105 and 106: 90 Luptrawan et al. Figure 2 Repres
Page 107 and 108: 92 Luptrawan et al. state (50). Pat
Page 109 and 110: 94 Luptrawan et al. ability of TIL
Page 111 and 112: 96 Luptrawan et al. Figure 4 Drug s
Page 113 and 114: 98 Luptrawan et al. Figure 6 Tumor
Page 115 and 116: Table 1 Summary of results of phase
Page 117 and 118: 102 Luptrawan et al. Table 1 Summar
Page 119 and 120: 104 Luptrawan et al. antigens (84,8
Page 121 and 122: 106 Luptrawan et al. 30. Ranges GE,
Page 123 and 124: 108 Luptrawan et al. 66. Dunn GP, B
Page 125 and 126: 110 Schroter and Minev proteins (2,
Page 127 and 128: 112 Schroter and Minev tumor-challe
Page 129 and 130: 114 Schroter and Minev Table 1 Inve
Page 131 and 132: 116 Schroter and Minev Table 1 Inve
Page 133 and 134:
118 Schroter and Minev demonstrated
Page 135 and 136:
120 Schroter and Minev loaded MART-
Page 137 and 138:
122 Schroter and Minev illustrate t
Page 139 and 140:
124 Schroter and Minev 4. Heemels M
Page 141 and 142:
126 Schroter and Minev 42. Minev BR
Page 143 and 144:
128 Schroter and Minev 74. Restifo
Page 146 and 147:
7 Multimodality Immunization Approa
Page 148 and 149:
Multimodality Immunization Approach
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Figure 5.1 Immunohistochemical char
Page 164 and 165:
Figure 8.5 A schematic representati
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
8 Bidirectional Bedside Lab Bench P
Page 172 and 173:
Development of Novel Immunotherapeu
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
9 Diagnostic Approaches for Selecti
Page 202 and 203:
Diagnostic Approaches to Maximize T
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222:
Page 225 and 226:
206 Index Antigenic peptides degrad
Page 227 and 228:
208 Index Chromogens, enzymatic act
Page 229 and 230:
210 Index Freund’s adjuvants. See
Page 231 and 232:
212 Index Langerhans cells, 133, 13
Page 233 and 234:
214 Index [Peptide vaccines] invest
Page 235 and 236:
216 Index TCRL. See TCR-like immuno
Page 238:
Oncology and Immunology about the b
show all

Download File - JOHN J. HADDAD, Ph.D.

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?